Viridian Therapeutics' Elegrobart Achieves Positive Phase 3 Results; Q1 Net Loss $104.9M, Cash $762.2M
VRDN is trading near its 52-week low of $11.76 (13% above the low).
Summary
Viridian Therapeutics reported its Q1 2026 financial results, including a net loss of $104.9 million and a robust cash position of $762.2 million. Crucially, the company announced positive topline results from both pivotal Phase 3 trials (REVEAL-1 and REVEAL-2) for elegrobart (VRDN-003) in Thyroid Eye Disease (TED), with both Q4W and Q8W dosing arms meeting primary endpoints and demonstrating a favorable safety profile. This significant clinical milestone follows the company's prior advancements in its TED pipeline, as noted in its last 10-K. The positive Phase 3 data for elegrobart substantially de-risks a key pipeline asset and expands Viridian's potential in the TED market. Traders will now focus on the upcoming PDUFA decision for veligrotug on June 30, 2026, for which the company is launch-ready, and the planned BLA submission for elegrobart in Q1 2027.
At the time of this announcement, VRDN was trading at $13.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $11.76 to $34.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.